Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone- refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
NeuroInsights is the world's leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment information, industry events and strategic advisory services to venture funds, startups, corporations, governments and financial institutions. For more information, visit http://www.neuroinsights.com.
NASDAQ is the largest U.S. equities exchange. With approximately 3,200
companies, it lists more companies and, on average, trades more shares per
day than any other U.S. market. It is home to companies that are leaders
across all areas of business including technology, retail, communications,
financial services, transportation, media and biotechnology. NASDAQ is the
primary market for trading NASDAQ-listed stocks as well as a leading
liquidity pool for trading NYSE-listed stocks. For more information about
NASDAQ, visit the NASDAQ Web site at http://www.nasdaq.com or the NASDAQ
|SOURCE Medivation, Inc.|
Copyright©2007 PR Newswire.
All rights reserved